Patritumab deruxtecan is under clinical development by and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Patritumab deruxtecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Smarter leaders trust GlobalData

Data Insights

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Patritumab deruxtecan overview

Patritumab deruxtecan (U-31402) is under development for the treatment of HER3-positive metastatic or unresectable breast cancer,  leptomeningeal disease from advanced solid tumors, human epidermal growth factor receptor 2 negative breast cancer, squamous or non-squamous non-small cell lung cancer, melanoma, intestinal cancer, ovarian cancer, cholangiocarcinoma, prostate cancer, head and neck squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, gastric cancer, gastroesophageal junction adenocarcinoma and triple negative breast cancer. It is administered intravenously. The drug candidate is an antibody-drug conjugate which consists of a fully human anti-HER3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload. It is being developed based on proprietary payload and linker-payload technology. 

It was under development for the treatment of metastatic colorectal cancer, colon cancer, rectal adenocarcinoma, bladder cancer and skin cancer.

Daiichi Sankyo overview

is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company鈥檚 other research areas include rare diseases and immune disorders. sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. is headquartered in Tokyo, Japan.

For a complete picture of Patritumab deruxtecan’s drug-specific PTSR and LoA scores,

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData鈥檚 Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData鈥檚 .